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Abstract 
The traditional oral pharmacological therapy for type 2 diabetes mellitus (T2DM) has been based on the prescrip-
tion of metformin, a biguanide, as first line antihyperglycemic agent world over. It has been demonstrated that 
after 3 years of treatment, approximately 50 % of diabetic patients could achieve acceptable glucose levels with 
monotherapy; but by 9 years this had declined to only 25 %. Therefore, the implementation of a combined pharma-
cological therapy acting via different pathways becomes necessary, and its combination with a compound of the 
sulfonylurea group was along decades the most frequently employed prescription in routine clinical practice. Meg-
litinides, glitazones and alpha-glucosidase inhibitors were subsequently developed, but the five mentioned groups 
of oral antihyperglycemic agents are associated with variable degrees of undesirable or even severe cardiovascular 
events. The gliptins—also called dipeptidyl peptidase 4 (DPP4) inhibitors—are an additional group of antidiabetic 
compounds with increasing clinical use. We review the status of the gliptins with emphasis on their capabilities to 
positively or negatively affect the cardiovascular system, and their potential involvement in major adverse cardio-
vascular events (MACE). Alogliptin, anagliptin, linagliptin, saxagliptin, sitagliptin, teneligliptin and vildagliptin are the 
compounds currently in clinical use. Regardless differences in chemical structure and metabolic pathways, gliptins as 
a group exert favorable changes in experimental models. These changes, as an almost general rule, include improved 
endothelial function, reduction of inflammatory markers, oxidative stress ischemia/reperfusion injury and atherogen-
esis. In addition, increased adiponectin levels and modest decreases in lipidemia and blood pressure were reported. 
In clinical settings, several trials—notably the longer one, employing sitagliptin, with a mean follow-up period of 
3 years—did not show an increased risk for ischemic events. Anyway, it should be emphasized that the encouraging 
results from basic science were not yet translated into clinical evidence, probably due the multiple and pleiotropic 
enzymatic effects of DPP4 inhibition. Moreover, when employing saxagliptin, while the drug was not associated with 
an augmented risk for ischemic events, it should be pinpointed that the rate of hospitalization for heart failure was 
significantly increased. Gliptins as a group constitute a widely accepted therapy for the management of T2DM, usually 
as a second-line medication. Nonetheless, for the time being, a definite relationship between gliptins treatment and 
improved cardiovascular outcomes remains uncertain and needs yet to be proven.
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Review
Background
The traditional oral pharmacological therapy for type 
2 diabetes mellitus (T2DM) has been based on the pre-
scription of metformin as first line antihyperglycemic 
agent world over. This biguanide derivate is the most 
widely prescribed drug to manage glucose metabolism 
in individuals with T2DM and is still recommended, 
in conjunction with lifestyle modification, as a first line 
medication in the joint guidelines of the American Dia-
betes Association and the European Association of the 
Study of Diabetes [1]. It has been demonstrated that 
after 3 years of treatment, approximately 50 % of diabetic 
patients could achieve acceptable glucose levels with 
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monotherapy; but by 9  years this had declined to only 
25  % [2]. Therefore, the implementation of a combined 
pharmacological therapy acting via different biochemical 
pathways becomes necessary, and its combination with a 
compound of the sulfonylurea group was along decades 
the most frequently employed prescription in routine 
clinical practice [3]. While it is generally considered a rel-
atively safe drug, increased mortality associated with the 
use of metformin was reported during long [4] and even 
short-term follow-up [5]. Appearance of lactic acidosis 
has been reported as well, especially in the elderly and in 
patients with liver failure [6, 7].
Cardiovascular derangement has been widely described 
for most sulfonylureas, which exert their action by clos-
ing the ATP-dependent potassium channels; this feature 
is accountable for both the insulinotropic and the unde-
sirable effects on the heart. During myocardial ischemia, 
sulfonylureas partially inhibit channels opening, avoiding 
so the required hyperpolarization that protects the cell by 
impeding calcium influx (the so-called “ischemic precon-
ditioning”) [8, 9]. In a population of coronary patients, 
data from our laboratory indicated a huge increased all-
cause crude mortality over a mean 7.7-year follow-up in 
diabetics on combined treatment with metformin and 
glibenclamide; figures on mortality in this group almost 
quadrupled those of nondiabetic coronary patients [10]. 
Similar findings have been reported in a general diabetic 
population [11], and the increased morbidity and mortal-
ity of this combined therapy was recently confirmed in a 
large nationwide Danish study [12]. Glinide compounds 
like repaglinide—which also act by closing the ATP-
dependent potassium channels—appear to be associated 
with a similar risk of adverse cardiovascular sequelae 
than sulfonylureas [13].
Regarding glitazones, these compounds have been 
associated with a higher risk of developing stroke, heart 
failure and all-cause mortality [14–17]. These excess risks 
were largest in people aged 65 years or older, and espe-
cially in patients treated with rosiglitazone [15].
Concerning alpha-glucosidase inhibitors, voglibose was 
found to improve endothelial function in patients with 
type 2 diabetes [18] and miglitol enhanced postprandial 
endothelial function in patients with acute coronary syn-
drome and new-onset postprandial hyperglycemia [19]. 
Moreover, acarbose has been postulated as a potential 
agent for coronary disease secondary prevention [20, 21]. 
Despite these promising perspectives, no unequivocal ben-
efits have been established since in a recent large intention-
to-treat analyses, acarbose was associated with a higher risk 
of development of any cardiovascular event, heart failure, 
and ischemic stroke compared to metformin [22].
As stated above, the five mentioned groups of oral 
antihyperglycemic agents—biguanides, sulfonylureas, 
meglitinides, glitazones and alpha-glucosidase inhibi-
tors—are associated with variable degrees of undesir-
able or even severe cardiovascular events. Moreover, 
the adequate treatment in case of comorbidities is not 
defined [23]. Taking these facts into consideration, the 
Food and Drug Administration (FDA) recommended 
that in order to establish the safety of a new antidiabetic 
therapy for T2DM, the manufacturers or sponsors should 
demonstrate that the new drug will not result in an unac-
ceptable increase in cardiovascular risk and the trials 
population should also include high risk patients. Other 
criteria included trials duration of at least 2 years [24]. A 
sixth pharmacological group, the gliflozins, constitutes 
a new category, and its yet unknown long-term cardio-
vascular outcome is currently being investigated [25]. 
The gliptins—also called dipeptidyl peptidase-4 (DPP4) 
inhibitors—are an additional group of antidiabetic com-
pounds with increasing worldwide clinical use since the 
first of them, sitagliptin, got the FDA approval in 2006 
[26]. In this context, the purpose of the present article 
is to review the status of the gliptins currently in clinical 
use, with special emphasis on their capabilities to posi-
tively or negatively affect the cardiovascular system, and 
their potential involvement in major adverse cardiovas-
cular events (MACE).
Biochemistry
Dipeptidyl peptidases are a family of several complex 
proteases with similar chemical structure; the biological 
roles and identity of their endogenous substrates remains 
poorly understood for the majority of them [27]. There-
fore, a cautious evaluation of the selectivity and speci-
ficity of any pharmacological compound used to inhibit 
DPP4 activity is required [28]. For the time being, DPP4 
is the best known member of the family and acts as a 
membrane-anchored cell surface peptidase transmitting 
intracellular signals through a short intracellular tail. In 
humans, the DPP4 gene is located on chromosome 2 
locus 2q24.3 and composed of 26 exons that encode a 
protein of 766 amino acids [29]. DPP4 is widely expressed 
in several cell types, particularly in exocrine glands and 
absorptive epithelia. It is mainly found in the brush bor-
ders of epithelial cells of the proximal convoluted tubules 
in the kidney, in the small and large intestine, prostate 
tissue, hepatocytes, fibroblasts and in activated leuko-
cytes [30–33], preferentially cleaving peptide hormones 
containing a position two alanine or proline [27].
The incretins are gut-derived hormones, constituents 
of the glucagon superfamily, released in response to 
nutrient ingestion, mainly sugars and fat. They put forth 
a wide range of effects, including stimulation of pan-
creatic insulin secretion in a glucose-dependent man-
ner and play a central role in local gastrointestinal and 
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whole-body physiology. The principal incretins are the 
glucose-dependent insulinotropic polypeptide (GIP) 
and the glucagon-like peptide-1 (GLP-1), representing 
the endogenous physiological substrates for DPP4 activ-
ity [34, 35]. GIP is secreted from the L-cells of the dis-
tal ileum and colon and GLP-1 from the K-cells in the 
duodenum and jejunum [36]. GLP-1 is stronger than 
GIP regarding insulinotropic activity, and their biologi-
cal activity is cumulative. GIP has a half life of approxi-
mately 7 min, much longer than the 2 min documented 
for GLP-1 [27, 37, 38]. Therefore, taking into considera-
tion the DPP4 mechanism of action, its pharmacological 
inhibition by gliptines will avoid interaction with its sub-
strates, increasing plasmatic GIP and GLP-1 concentra-
tions and stimulating insulin biosynthesis [39].
Gliptins comprise a diverse group of compounds, which 
from a pharmacokinetic point of view can be broadly 
divided into peptidomimetics and non-peptidomimetics. 
Both are competitive reversible inhibitors of the DPP4 
substrate acting extracellularly. The former are nitrile-
containing inhibitors that act on the DPP4 substrate 
involving production of a reversible covalent enzyme–
inhibitor complex, which gradually and slowly dissociates 
from the substrate leading to a lasting inhibitory activity, 
even after the drug has been inactivated. This phenom-
enon explains why these compounds act for longer than 
the relatively short half-lives of most of them would sug-
gest. On the contrary, non-peptidomimetic drugs yield 
to a non-covalent extracellular cross-talk with residues 
in the catalytic site of the DPP4 substrate, resulting in a 
strong and immediate inhibition [40–43]. It has been sug-
gested that these differences between compounds may 
also be reflected in their cardiovascular effects [44]. The 
differences in the metabolic pathways are also expressed 
in the therapeutic doses, which may range from 5 mg for 
saxagliptin to 100  mg for sitagliptin, and in the dosing 
frequency. The currently most used compounds include 
alogliptin [45–48], anagliptin [49–52], linagliptin [44, 
53–56], saxagliptin [57–59], sitagliptin [60], teneliglip-
tin [61] and vildagliptin [62]. Data regarding approving 
authority, chemistry, half life, dosage and catabolic path-
way are summarized in Table  1. The research regarding 
an additional drug, dutogliptin, was discontinued [63], 
while several another compounds, notably gemigliptin 
[64] (already approved in South Korea) are currently at 
diverse stages of development and evaluation. Trelaglip-
tin, a compound that unlike other approved agents of its 
class—which are usually administered once daily—can 
be administered once weekly, has been recently approved 
in Japan [65], and studies on another long-acting drug, 
omarigliptin, are in progress [66].
Pharmacological interactions
In daily clinical practice, gliptins are almost usually pre-
scribed together with other antidiabetic, antihypertensive 
and antihyperlipidemic agents. Therefore, it is of utmost 
importance to establish whether potential undesirable 
interactions may be present. No adverse events were dis-
closed in the co-administration with metformin [67–69], 
glibenclamide [70], glitazones [71, 72], and simvastatin 
[73]. Moreover, in an experimental murine model, the 
combination with valsartan improved both pancreatic 
beta-cell function and insulin sensitivity, with a reduc-
tion of the inflammatory and cell stress milieu [74]. It 
should be mentioned that some gliptins, like linagliptin 
and saxagliptin may be metabolized via the CYP3A4 or 
CYP3A4/5 pathways, and this could result in a dimin-
ished clearance of other drugs using the same pathways. 
In addition, a reduction in the dose of sulfonylureas is 
usually recommended when a gliptin is added, since its 
pharmacodynamic interaction with the sulfonylurea may 
result in a higher risk of hypoglycemia. Anyway, this issue 
does not seem to be of clinical relevance [75]. As a gen-
eral rule, there is no great propensity for the gliptins to 
be involved in any significant drug interaction with com-
monly prescribed antidiabetic medicines [42, 43].
Table 1 Gliptins summarized data on approving authority, pharmacokinetics, chemistry, half life, dosage and catabolic 
pathway
a In addition, <10 h of partially active metabolite
b In addition, <7 h of partially active metabolite
Compound Approval Peptidomimetic Chemistry Maximal  
half life, hours
Usual dose, mg Main catabolic 
pathway
Alogliptin FDA, 2013 – Pyrimidinedione <21 25 qd Renal
Anagliptin Japan, 2012 + Cyanopyrrolidine <4.5a 100 bid Renal
Linagliptin FDA, 2011 – Xanthine <40 5 qd Biliary
Saxagliptin FDA, 2009 + Cyanopyrrolidine <4b 5 qd Renal
Sitagliptin FDA, 2006 – Beta-amino acid <24 100 qd Renal
Teneligliptin Japan, 2012 + Prolylthiazolidine <24 20 qd Renal
Vildagliptin European Union, 2007 + Cyanopyrrolidine <4.5 50 bid Renal
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Cardiovascular effects of currently used gliptins
Sitagliptin
The effects of this medication—a beta-amino acid—on 
cardiovascular outcomes in patients with T2DM have 
been recently reported by Green et  al. in the Trial to 
Evaluate Cardiovascular Outcomes after Treatment 
with Sitagliptin (TECOS) [60]. This is a randomized 
double-blind open-label study including nearly 15,000 
patients in which co-administration of either sitaglip-
tin or placebo was implemented on top of their previ-
ous antidiabetic treatment. The included patients had 
T2DM and proven cardiovascular disease and were 
at least 50  years old, with glycated hemoglobin levels 
of 6.5–8.0  % when treated with stable doses of one or 
two oral antihyperglycemic agents (metformin, piogl-
itazone, or a sulfonylurea) or insulin (with or without 
metformin). Sitagliptin dose was of 100  mg daily, or 
50  mg daily in cases of kidney dysfunction. A com-
posite of cardiovascular death, nonfatal myocardial 
infarction (MI), nonfatal stroke, or hospitalization for 
unstable angina was established as primary cardio-
vascular outcome. The secondary composite cardio-
vascular outcome was defined as the first confirmed 
event of cardiovascular death, nonfatal MI, or nonfatal 
stroke. In addition, other secondary outcomes com-
prised occurrence of the individual components of the 
primary composite cardiovascular outcome, fatal and 
nonfatal MI, fatal and nonfatal stroke, death from any 
cause, and hospitalization for heart failure. The study 
showed that after a mean follow-up period of 3  years, 
the addition of sitagliptin to the conventional pharma-
cological treatment did not have a significant effect on 
rates of major adverse cardiovascular events or hospi-
talization for heart failure. This study confirmed the 
findings of an earlier pooled analysis of 25 randomised 
clinical trials totalizing—similarly to the TECOS trial—
almost 15,000 patients, which did not indicate that 
treatment with sitagliptin increases cardiovascular risk 
in patients with T2DM [76].
Data from other studies reported several beneficial 
effects. Indices of glycemic control, such as hemoglobin 
A1c, glycated albumin, and 1.5-anhydro-d-glucitol were 
significantly improved after a 3-month treatment with 
sitagliptin, and serum adiponectin level was significantly 
increased without changes of body weight [77]. Endothe-
lial function was improved as well [18]. It was also sug-
gested that previous chronic treatment with sitagliptin 
may have cardioprotective effects in diabetic patients 
presenting with acute coronary syndrome [78]. Moreo-
ver, in patients who were at high risk of heart failure after 
acute coronary syndrome, sitagliptin exposure was not 
associated with an increased risk of de novo heart failure 
[79] or other adverse cardiovascular events [80].
Saxagliptin
Saxagliptin, a cyanopyrrolidine, was the second gliptin 
that obtained the FDA approval. A comprehensive study 
including about 16,500 patients followed for a median 
of 2.1 years and describing the cardiovascular outcomes 
of this medication was reported by Scirica et  al. in the 
SAVOR-TIMI 53 trial [58]. Patients with T2DM with 
documented or at risk for cardiovascular events were 
randomly assigned to receive saxagliptin or placebo. The 
usual dose was 5  mg daily, and the primary end point 
a composite of cardiovascular death, MI or ischemic 
stroke, and the main secondary end point a composite 
of cardiovascular death, MI, stroke, hospitalization for 
unstable angina, coronary revascularization, or heart 
failure. The study demonstrated that saxagliptin did not 
increase or decrease the rate of ischemic events. Subse-
quently, an analysis of pooled data from 20 clinical trials 
comprising over 9000 patients with T2DM confirmed 
that the drug was not associated with an increased risk 
for ischemic events [57]. Anyway, it should be specially 
pinpointed that the rate of hospitalization for heart fail-
ure was increased [58, 81–83]—in contrast to the find-
ings reported for sitagliptin [60, 79]. Moreover, the risk of 
heart failure hospitalization was augmented irrespective 
of age category [84], being highest among patients with 
elevated levels of natriuretic peptides, previous heart fail-
ure, or chronic kidney disease [85].
Linagliptin
Linagliptin is a potent gliptin with a xanthine-based 
molecular structure [86–88]. It inhibits DPP4 competi-
tively and reversibly, showing a slow rate of dissociation 
from the active center of the DPP4 enzyme molecule, 
and regarding selectivity towards DPP4 in comparison 
to other enzymes of the DPP family, it is 40,000-fold 
higher towards DPP-4 than towards DPP-8 and >10,000-
fold higher towards DPP-9 [89]. Linagliptin is rapidly 
absorbed after oral administration with a Tmax of 0.7–3 h 
that does not differ between healthy and T2DM subjects 
after single or multiple doses [90–92]. A pre-specified 
patient-level pooled analysis of all available double-blind, 
randomized, controlled trials evaluating the cardiovas-
cular safety of the drug has been recently published [54]. 
The study encompassed 19 trials of ≥12  weeks’ dura-
tion, including nearly 9500 subjects receiving linagliptin 
versus placebo or another active treatment. Out of these 
patients, about 5850 received linagliptin; most of them 
5 mg daily. The comparators were glimepiride, voglibose 
and placebo. The primary end point was time to the first 
occurrence of any components of the 4P-MACE compos-
ite, i.e. cardiovascular death (including fatal stroke and 
fatal MI), non-fatal MI (excluding silent MI), non-fatal 
stroke or hospitalization for unstable angina pectoris. 
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The main limitation of this study is the mean duration of 
the included trials, considerably shorter than the recom-
mended by the FDA [24], reducing so the extent of inter-
pretations that can be made. Anyway, the incidence rate 
of 4P-MACE was 13.4 events per 1000 patient-years for 
linagliptin-treated patients compared with 18.9 in the 
active comparator group; therefore it should be pointed 
out that linagliptin was not associated with an increase in 
cardiovascular risk.
Two ongoing trials will provide a more definitive 
answer on the cardiovascular safety profile of linaglip-
tin. The first is the CAROLINA trial [93, 94], started in 
2010, that has randomized more than 6000 patients with 
early T2DM and predominantly medium cardiovascular 
risk, to treatment with either linagliptin or glimepiride. 
Therefore, it is the first head-to-head outcome trial of 
a gliptin versus an active comparator that is sufficiently 
powered to unveil potential differences in MACE occur-
rence between treatment groups [54]. The second one 
is the CARMELINA trial, initiated in 2013 and aimed 
to investigate the long term impact on cardiovascu-
lar morbidity, mortality and renal function in a selected 
population of 8300 patients with T2DM and renal com-
promise, comparing outcomes against placebo, on a 
background of standard of care [95]. The results of both 
trials are expected in 2018. For the time being, the avail-
able information regarding linagliptin and kidney func-
tion is encouraging [96–98]. In addition, it has been 
documented that linagliptin ameliorates cardiovascular 
injury in salt-sensitive hypertensive rats independently of 
blood glucose and blood pressure [44], and also attenu-
ates neointima formation after vascular injury and vascu-
lar smooth muscle cells (VSMC) proliferation beyond its 
glucose-lowering effect [56].
Alogliptin
Alogliptin is a pyrimidinedione derivative highly selec-
tive gliptin, rapidly absorbed, with a mean time to max-
imum concentration (Cmax) of approximately 1–2  h 
[99–101]. Preliminary clinical studies reported favora-
ble results [102, 103]. The EXAMINE trial was pro-
grammed in order to assess its cardiovascular safety in 
T2DM patients with acute coronary syndrome [104]. It 
was a multicentre, double-blind trial, into which 5380 
subjects—enrolled from 49 countries—who underwent 
such an event event in the previous 15–90  days were 
randomly assigned to alogliptin 25  mg daily or placebo 
plus standard treatment for diabetes and cardiovascular 
disease prevention. The results have been recently pub-
lished [105]. The pre-specified MACE endpoint was all-
cause mortality, non-fatal MI, non-fatal stroke, urgent 
revascularization for unstable angina syndrome, and hos-
pitalization for heart failure. Alogliptin neither increased 
cardiovascular morbidity or mortality, nor worsened pre-
existing heart failure, including in those patients with a 
very recent acute coronary syndrome, after a median 
duration treatment of 18 months [106, 107]. In addition, 
assessment of N-terminal pro-BNP (NT-pro-BNP) con-
centration from baseline to 6 months did not reveal any 
significant changes.
The safety of the co-administration of alogliptin and 
pioglitazone has been documented in both clinical [48, 
107] and experimental [108] settings. Moreover, addi-
tional beneficial effects have been described. The drug 
attenuates arterial inflammation and neointimal forma-
tion after injury in low-density lipoprotein receptor-defi-
cient mice [109] and—besides the expected decrease in 
glucose and hemoglobin A1c—leads also to a decrease 
in serum lipids in humans [110]. A preliminary report 
indicates that in the postprandial state lipemia dimin-
ishes, and endothelial dysfunction improves in non-dia-
betic subjects [111]. An anti-arrhythmogenic effect was 
described in rabbits via augmentation of atrial angiogen-
esis [112].
Vildagliptin
Vildagliptin is a cyanopyrrolidine derivative [113–115]. A 
large retrospective meta-analysis of prospectively adjudi-
cated cardiovascular events has been recently published, 
including data from 40 double-blind, randomised-con-
trolled phase III and IV studies encompassing about 
17,500 patients (mean age 57  years) receiving vildaglip-
tin 50 mg once and twice daily, or comparators [116]. The 
primary endpoint was occurrence of any MACE. The 
duration of the trials was very variable, lasting from 12 
up to 104 weeks, and the average length of treatment was 
about 1  year. The results indicated that the medication 
was not associated with an increased risk for adjudicated 
MACE relative to comparators. Moreover, the event rates 
for new onset of heart failure or hospitalization for its 
aggravation were relatively low (0.4 %) and similar both 
groups.
Another vildagliptin trial is the VISUAL study [117]. 
The study was aimed to compare the efficacy and safety 
of adding vildagliptin with sulfonylurea dose-increasing 
as an active comparator in patients with inadequately 
controlled T2DM using metformin plus sulfonylurea in 
a real clinical setting. The study demonstrated that the 
vildagliptin add-on group exhibited no clinically relevant 
weight gain and had a lower incidence of hypoglycemia 
compared with the sulfonylurea group, and the addition 
of vildagliptin to sulfonylurea could be considered as a 
treatment option prior to intensification with insulin 
[118].
In rodent models, vildagliptin enhanced blood flow 
recovery and capillary density in ischemic limbs with 
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accompanying increases in endothelial nitric-oxide syn-
thase [119] and prevented left ventricular hypertrophy 
caused by continuous beta-adrenergic stimulation by iso-
proterenol [120].
Anagliptin
Like saxagliptin and vildagliptin, anagliptin is a cyano-
pyrrolidine derivative possessing a prolylprolinenitrile 
scaffold [113, 121], available for clinical use in Japan since 
2012. Since this compound is not generally used in coun-
tries other than Japan, there is a paucity of reports inves-
tigating its effects. The recommended dose of is 200 mg 
daily (100  mg bid), albeit increases in the dose up to 
400  mg daily have been approved in cases in which the 
blood glucose-lowering effect is unsatisfactory [52].
Besides its hypoglycemic effects, a pooled analysis of 
data obtained from Phase III trials, the serum LDL-cho-
lesterol, triglycerides, total cholesterol and non-high-
density lipoprotein-cholesterol levels were significantly 
reduced after the administration of anagliptin at doses of 
200 or 400 mg [122]. Moreover, it has been demonstrated 
in a model of apoE-deficient mice that anagliptin reduced 
the area of atherosclerotic lesions, suggesting thus a 
potential anti-atherogenic action via direct inhibition of 
smooth muscle cell proliferation and inflammatory reac-
tion of monocytes [123].
Teneligliptin
Teneligliptin is a prolylthiazolidine [61] approved for 
the treatment of T2DM in Japan in 2012 and in South 
Korea in 2014 [124, 125]. A 4-week, randomized, dou-
ble-blind, placebo-controlled trial showed a significantly 
improved 24-h blood glucose control [126], and a subse-
quent pooled post hoc analysis including more than 700 
patients provides evidence of the safety and efficacy of 
a 52 weeks mean follow-up of use of teneligliptin 20 mg 
daily as monotherapy or in combination with sulfony-
lurea, glinide, biguanide or α-glucosidase inhibitor in 
Japanese patients with T2DM [127]. The dose can be 
increased up to 40  mg per day [128]. Teneligliptin was 
also used as an initial monotherapy for drug-naive newly 
diagnosed T2DM subjects. It activated beta-cell function 
and decreased insulin resistance, being rather effective in 
reducing both fasting blood glucose levels and HbA1c. 
However, a significant increase in uric acid concentration 
was observed in some patients [129].
Regarding the cardiovascular effects, it should be 
pinpointed that QT/QTc evaluations were performed 
for this compound [128]. No QT prolongations were 
detected with 40  mg daily of teneligliptin, which is the 
maximal dose in usual clinical practice. Anyway, a mild 
QTc transient prolongation was documented while using 
supraclinical dosages. Therefore, caution is needed if the 
drug is used for a long period or in co-administration 
with medications known to cause QT prolongation on 
their own [128]. On the other hand, teneligliptin treat-
ment was associated with improvements in left ventric-
ular function—particularly diastolic—and endothelial 
functions, as well as with an increase in serum adiponec-
tin levels [130].
Mechanistic construal
Which could be the molecular mechanisms for the 
favorable results of DPP4 inhibition in experimental 
settings? Several responses can be outlined. DPP4 is 
a transmembrane glycoprotein that cleaves N-termi-
nal dipeptides from many substrates. It is ubiquitously 
expressed, including several growth factors, hormones, 
neuropeptides, and chemokines [30, 33, 131]. Using a 
proteomics approach, human adipocytes’ secretome 
has been unveiled, identifying DPP4 as a newfangled 
adipokine, produced particularly by fully differentiated 
adipocytes [132, 133]. Anyway, it should be emphasized 
that the main divergence with many other adipokines 
is that DPP4 is not directly secreted by adipocytes but 
released from the plasma membrane as soluble DPP4 
following proteolytic cleavage [32, 134]. Soluble DPP4 
is a striking activator of both mitogen-activated pro-
tein kinases (MAPK) and nuclear factor kappa B (NF-
κB); these pro-inflammatory signaling pathways lead to 
proliferation and atherogenic transformation of VSMC 
[133]. A DPP-4 inhibitor exerts anti-inflammatory effects 
on macrophages and adipocytes, being able to suppress 
NF-κB activation [135]. In this context, soluble DPP4 
also induces activation of extracellular-signal-regulated 
kinases (ERKs, a specific subset of the MAPK family) in 
VSMC, which was partially blocked by DPP4 inhibition 
[123]. The main effects of this inhibition are depicted in 
Fig. 1.
DPP4 consistently impaired insulin signaling at the 
level of protein kinase B (the so-called Akt) in several 
primary cell types like adipocytes, skeletal muscle, and 
VSMC [132]. In addition, it has been shown that while 
a trend for higher DPP4 expression in visceral fat is pre-
sent lean subjects, in obese subjects DPP4 is significantly 
higher in visceral adipose tissues than in its subcutane-
ous counterparts [132]. DPP4 expression in both adi-
pose depots is significantly higher in obese compared 
with lean subjects, and its levels positively correlate 
with body mass index (BMI), subcutaneous and visceral 
adipocytes size, insulin, and leptin [132, 136], whereas 
a negative correlation with age and adiponectin was 
found [132, 137]. High DPP4 activity might induce sub-
sequent accumulation of body fat and increased BMI 
[138], and in turn long-term obesity and lipid accumula-
tion will lead to insulin resistance and hyperglycemia via 
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abnormally obesity-linked down-regulation of adiponec-
tin [139]. Moreover, an increased DPP4 production from 
adipocytes is observed in both type 1 and T2DM [140]. 
Together, all these biochemical facts represent a mecha-
nistic construal reflecting a solid scaffold for the alleged 
beneficial cardiovascular outcomes obtained by inhibi-
tion of DPP4 activity.
Therefore, besides their glucose-lowering activ-
ity, gliptins have an intrinsic manifold cardiovascular 
impact. This impact is rooted in the fact that the pres-
ence of GLP-1 receptors in human cardiac myocytes 
has been demonstrated two decades ago [141] and sub-
sequently confirmed in later years [142, 143], boosting 
the interest of researchers to properly establish the rel-
evance of the gliptin-induced changes in clinical settings. 
As mentioned above, the changes are explained by rea-
sonable molecular mechanisms and seem to be mainly 
beneficial. They include improvement of endothelial 
function, decrease of inflammatory markers, reduction of 
ischemia/reperfusion injury in experimental models, pre-
vention of left ventricular remodeling, modest decreases 
in blood pressure and lipidemia, and a trend to lower 
MACE incidence.
Controversial issues
Unfortunately, the above mentioned favorable features 
are counterbalanced by other ones. For instance, in addi-
tion to inactivate the incretin hormones, DPP4 can also 
affect the orexigenic hormone neuropeptide Y, and its 
inhibition by gliptines enhances antilipolytic action in 
human adipose tissue leading to further accumulation of 
body fat [144, 145]. Additional important points repre-
sent a source of concern, such as the significantly higher 
rate of hospitalization for heart failure with saxagliptin 
Fig. 1 Schematic depiction of the main biochemical and clinical effects of DPP4 (dipeptidyl peptidase-4) inhibition. While both the increasing 
(green arrows) and decreasing (blue arrows) effects seem to be favorable, the overall influence on MACE (major adverse cardiovascular events) 
remains uncertain
Page 8 of 13Fisman and Tenenbaum  Cardiovasc Diabetol  (2015) 14:129 
reported in the SAVOR-TIMI 53 trial [58], the fact that 
the research regarding dutogliptin—initially considered 
a promising selective DPP4 inhibitor [146] was abruptly 
discontinued without giving any reason [63] and the find-
ing of hyperuricemia in patients treated with teneligliptin 
[129]. A recent assessment of the results of the EXAM-
INE trial [105] points out that the rate of heart failure was 
increased in patients on alogliptin who had no previous 
history of this disorder [147]. Moreover, the co-admin-
istration of gliptins with ACE-inhibitors or angiotensin 
receptor blockers maybe associated with severe angi-
oedema [148, 149], despite favorable metabolic effects in 
an experimental model [74].
Several explanations can be hypothesized regarding 
these conflicting results. In first place, gliptins are multi-
target compounds, and therefore their activity is con-
nected with the inhibition of various substrates, leading 
to undesirable effects [150]. Moreover, DPP4 inhibi-
tors may exert differential effects on substrate activ-
ity in a diabetic versus a normoglycemic setting [151] 
and chronic treatment with gliptins exerts progressive 
changes in metabolic parameters beyond those detected 
in single-dose administration studies [152]. Finally, most 
of the trials were not long enough to comply with the 
FDA recommendations regarding cardiovascular out-
comes [24].
Regardless the differences in their chemical structure 
and metabolic pathways, gliptins as a group constitute a 
widely accepted therapy for the management of T2DM, 
usually as a second-line medication [27, 42, 153–156]. It 
has neutral effects on weight [157, 158]; oral administra-
tion and low incidence of hypoglycemia are important 
advantages. On the other hand, while experimental and 
preliminary clinical studies on several surrogate end-
points suggest that gliptins can exert cardioprotective 
actions, the results of placebo-controlled phase IV trials 
have been rather disappointing so far. In clinical settings, 
several trials—notably the longer one, with sitagliptin—
did not show an increased risk for ischemic events [60], 
but the encouraging results from basic science were not 
yet translated into clinical evidence, probably due the 
pleiotropic enzymatic effects of DPP4 [159, 160]. The rel-
atively rapid FDA approval of sitagliptin for clinical use 
has been criticized [161], post-marketing reports reveal 
safety aspects that need further investigation [162], and 
it has even been suggested to restrict the use of gliptins 
to Phase IV clinical trials until cardiovascular safety is 
clearly established [163].
Conclusion
For the time being, a definite relationship between 
gliptins treatment and improved cardiovascular out-
comes remains uncertain and needs yet to be proven.
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